ESR1 and breast carcinoma: In the previous Creighton study, ER+ MCF-7 breast cancer cells were made to stably over-express EGFR or constitutively activate erbB-2, Raf, or MEK; which resulted in these cells exhibiting estrogen-independent growth and the down-regulation of ER expression.